Acute myeloid leukemia patient with active disseminated tuberculosis bridged to transplant with reduced 14-day venetoclax and azacitidine schedule

A 59-year-old female patient was diagnosed with acute myeloid leukemia and tuberculosis. As a further complication, she developed idiopathic bowel perforation. Her infectious and intestinal situation demanded shorter periods of neutropenia and did not permit a high-dose, curative therapy regimen. Moreover, simultaneous administration of venetoclax and antitubercular therapy with rifampicin causes CYP3A4 interactions and thereby higher levels of toxicity. She was treated with a shortened, 14-day therapy regimen with azacitidine and venetoclax as antileukemic treatment together with ethambutol, pyrazinamide, isoniazid, and rifampicin as antitubercular therapy, which resulted in a complete remission and to an improvement of the tuberculosis without any greater toxicity or other adverse events.